QNTM equity, liquidity strengthened as FDA approves Lucid-MS trial
Quantum BioPharma says it strengthens equity and liquidity in Q2 2026 following FDA approval of Lucid-MS for a pivotal Phase 2 clinical trial.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.